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P R E V I E W S
Human cancer stem cells, identified in
acute myelogenous leukemia (Bonnet and
Dick, 1997), myeloid blast crisis of chronic
myelogenous leukemia (Jamieson et al,
2004), breast cancer (Al-Hajj et al., 2003),
and brain tumors (Singh et al., 2003),
share functional properties with normal
stem cells, such as high proliferative
potential, some differentiation capacity,
and the ability to be serially transplanted
(reviewed in Passegué et al., 2003).
Signaling pathways involved in the regula-
tion of normal stem cell self-renewal are
frequently mutated or epigenetically acti-
vated in cancer, indicating that self-renew-
al, i.e. a cell division that produces
progeny identical to the parental cell, is a
vital property of cancer stem cells
(reviewed in Reya et al., 2001). Targeted
disruption of cancer stem cell self-renewal
would represent a novel therapeutic strat-
egy that could significantly reduce the
capacity of a tumor to propagate itself, and
could be employed in the eradication of a
broad spectrum of cancers, including
leukemias.
Chronic myelogenous leukemia
(CML) and most types of acute myeloge-
nous leukemia (AML) are induced by
leukemia-associated fusion proteins that
generally function as aberrantly activat-
ed signaling mechanisms or positive or
negative transcriptional regulators, and
directly interfere with the hematopoietic
differentiation program. While their
mechanism of action is relatively well
understood, little is known about their
developmental requirement for transfor-
mation and the role of self-renewal in this
process. In this issue of Cancer Cell,
Huntly et al. (2004) have studied in the
mouse the target cell requirement of two
human leukemia-associated fusion pro-
teins, MOZ-TIF2 and BCR-ABL. MOZ-
TIF2, an AML-associated fusion gene
resulting from the inv (8)(p11q13)-
induced juxtaposition of the MOZ chro-
matin remodeling gene and the TIF2
nuclear receptor transcriptional coactiva-
tor, is thought to modulate the transcrip-
tional activity of target genes through
aberrant histone acetylation. In contrast,
BCR-ABL, the hallmark of CML, gives
rise to a constitutively active protein tyro-
sine kinase, which endows primitive
stem and progenitor cells with a prolifer-
ative and survival advantage (reviewed
in Daley, 2004). Using retroviral gene
transfer combined with in vitro serial
replating assays and leukemic transplan-
tation into lethally irradiated recipient
mice, they compared the capacity of
MOZ-TIF2 and BCR-ABL to enhance the
self-renewal potential of normal murine
bone marrow mononuclear cells, highly
purified hematopoietic stem cells (HSC),
and more committed progenitors includ-
ing common myeloid progenitors (CMP)
and granulocyte-monocyte progenitors
(GMP). They also included critical con-
trols, such as MOZ-TIF2 point mutants
that lacked transforming activity, to
exclude a contribution by retroviral inser-
tional mutagenesis to the observed
leukemogenic effects. The results pre-
sented in this paper demonstrate that
MOZ-TIF2, but not BCR-ABL, endows
myeloid progenitors with self-renewal
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Leukemia stem cells are defined as transformed hematopoietic stem cells or committed progenitor cells that have ampli-
fied or acquired the stem cell capacity for self-renewal, albeit in a poorly regulated fashion. In this issue of Cancer Cell,
Huntly and colleagues report a striking difference in the ability of two leukemia-associated fusion proteins, MOZ-TIF2 and
BCR-ABL, to transform myeloid progenitor populations. This rigorous study supports the idea of a hierarchy among
leukemia-associated protooncogenes for their ability to endow committed myeloid progenitors with the self-renewal
capacity driving leukemic stem cell propagation, and sheds new light on the pathogenesis of chronic and acute myeloge-
nous leukemias.
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capacity, which leads to their immortal-
ization in vitro and to their ability to give
rise to AML following transplantation in
vivo. Interestingly, MLL-ENL, another
AML-associated fusion protein, also con-
tributes to the transformation of commit-
ted progenitors that normally lack
self-renewal capacity (Cozzio et al.,
2003), further underscoring the impor-
tance of acquisition of self-renewal
potential as a critical leukemogenic
event that supersedes other factors such
as the stage of commitment of the target
cell population. By extending such stud-
ies to other AML-associated fusion
genes, it should be possible to determine
whether capacity to confer self-renewal
potential is a defining criterion for onco-
genes involved in acute-phase diseases.
However, whether MOZ-TIF2 and MLL-
ENL result in the activation of the same
self-renewal target genes as those found
for other leukemia-associated transloca-
tion products (Alcalay et al., 2003), or
whether they induce self-renewal by
independent means, remains to be
determined.
BCR-ABL was the first leukemia-
associated translocation product to be
discovered and also the first target of
molecular therapy involving the tyrosine
kinase inhibitor imatinib. However, ima-
tinib has not prevented CML progression
in the majority of patients with advanced-
phase disease.This is expected of single
agent therapeutic targets wherein preex-
isting mutants or epigenetically altered
gene products in cancer cells result in
their emergence in a selection process,
as first exemplified in microbial genetics
(Luria and Delbruck, 1943; Lederberg,
1971). Resistance to imatinib in highly
leukemic cells may also suggest that
there are other potent transforming
events that are not affected, and that the
leukemia stem cell population harboring
these events may be impervious to cur-
rent forms of targeted therapy (reviewed
in Daley, 2004). Huntly and colleagues
demonstrate that leukemia-associated
fusion proteins differ in their capacity to
provide leukemogenic self-renewal
potential, which supports the idea of a
hierarchic order among the protoonco-
genic events that create leukemic stem
cells from cells of different developmen-
tal origins. While MOZ-TIF2 is transform-
ing at both the HSC and committed
myeloid progenitor levels, BCR-ABL is
incapable of transforming cells that lack
inherent self-renewal capacity; this is in
keeping with the previous characteriza-
tion of chronic phase CML as a
hematopoietic stem cell disease, and
demonstrates that leukemogenic effects
of individual oncogenes are cell-type-
and context-specific (Jamieson et al.,
2004; Passegué et al., 2004). The data
presented by Huntly and coworkers sug-
gest that BCR-ABL expression most like-
ly represents a preleukemic event that
provides a proliferative and survival
advantage to CML stem and progenitor
cells, but lacks the ability to endow self-
renewal potential, and thus is not fully
transforming when expressed in commit-
ted myeloid progenitors.
The pivotal work described in this
paper also provides important insights
into the multistep pathogenesis of
leukemias (Figure 1) and helps to distin-
guish the molecular mechanisms con-
trolling preleukemic events that impart a
proliferative advantage and leukemic
transforming events that confer a self-
renewal advantage. In chronic phase
CML, the preleukemic events most like-
ly occur at the level of the HSC, since
they are the only cells within the entire
hematopoietic system that live long
enough, due to self-renewal, to accu-
mulate such rare events. Examples of
preleukemic events include defects in
proliferation and survival as a result of
BCR-ABL expression, Bcl-2 overex-
pression or, as recently shown, loss of
JunB expression (Passegué et al.,
2004). The emergence of an acute dis-
ease, such as blast crisis phase CML or
AML, may occur when a preleukemic
HSC subset or a population derived
from preleukemic HSC gains self-
renewal potential and emerges as a
novel leukemic stem cell entity. Hence,
a preleukemic phase, in which HSC
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Figure 1. Oncogene hierarchy and role of
self-renewal in pathogenesis of leukemias
A: Normal myelopoiesis is distinguished by
the orderly differentiation of hematopoietic
stem cells (HSC), which are the only cells with
self-renewal capacity, into committed
myeloid progenitors and their respective ter-
minally differentiated progeny.
B: Chronic diseases, such as chronic phase
CML, are associated with preleukemic
events that result in increased survival and
proliferation within the stem and myeloid
progenitor populations but continued pro-
duction of terminally differentiated progeny.
Acquisition of BCR-ABL, overexpression of
Bcl2, and inactivation of JunB expression are
examples of such events that initially take
place in HSC.
C and D: Acute diseases such as blast crisis
CML and AML are marked by acquisition of
self-renewal capacity by progenitors that
normally lack it or by enhanced self-renew-
al in HSC. β-catenin activation during the
progression of CML to blast crisis is an exam-
ple of such a leukemogenic event occur-
ring in myeloid progenitors. MOZ-TIF2 and
MLL-ENL are AML-associated translocation products that may enhance HSC self-renewal or endow myeloid progenitors with self-renewal
potential. Together with a subsequent block in differentiation, these leukemogenic events result in the accumulation of immature blast prog-
eny and development of AML at either the HSC or myeloid progenitor stage.
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have acquired a number of mutations
and/or epigenetic events providing them
with a survival advantage, resistance to
programmed cell death, and extended
replicative lifespan, most likely facili-
tates the production of increased num-
bers of preleukemic clones that may
gain aberrant self-renewal capacity.
Amongst these preleukemic clones, the
stage is now set for the inexorable pro-
gression to acute leukemia at either the
HSC or myeloid progenitor stage. In
human blast crisis CML, this leukemic
evolution has been correlated with aber-
rant activation of the β-catenin pathway
that endows preleukemic GMP with
self-renewal potential and provides one
of the final hits required for full leukemic
transformation (Jamieson et al., 2004).
Unlike BCR-ABL, genes such as MOZ-
TIF2 or MLL-ENL can directly trigger
self-renewal pathways in cells that nor-
mally lack them or enhance self-renew-
al in cells that have inherent
self-renewal capacity. Together with
their capacity to induce or enhance self-
renewal, the ability of MOZ-TIF2 or
MLL-ENL to block differentiation results
in a much more potent oncogenic effect
leading directly to the development of
AML.
The elegant work performed by
Huntly and colleagues emphasizes the
critical role of self-renewal pathway acti-
vation in leukemia stem cell propagation
and the importance of understanding
these pathways and their effects at spe-
cific stages of hematopoietic develop-
ment. Future therapies aimed at
inhibiting the aberrant self-renewal
capacity of leukemic stem cell popula-
tions may provide a potent means of
preventing leukemic propagation, may
be used in concert with other targeted
therapies such as imatinib to ensure
complete eradication of leukemia, and
may be more broadly applicable in the
treatment of other malignancies that
have activated self-renewal pathways.
Finally, a thorough understanding of
molecular pathways involved in normal
versus cancer stem cell self-renewal
may provide important insights into the
self-renewal process driving normal
tissue regeneration, and consequently
may have applications in tissue
engineering.
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